November 19, 2024Clarametyx Bioscience Recognized as “Infectious Disease Innovation of the Year” In 2024 BioTech Breakthrough AwardsRead More October 17, 2024Clarametyx Biosciences Announces Progress on Study of Antibody Therapy CMTX-101 For Infections Associated With Cystic FibrosisRead More October 9, 2024Clarametyx to Present on Its Anti-Biofilm Technology Platform During Antimicrobial Pipeline Session At IDWeek 2024Read More May 28, 2024Clarametyx Biosciences Appoints Renowned Experts to Augment Strategic and Scientific Advisory BoardsRead More April 22, 2024Clarametyx Biosciences Expands Team Expertise to Accelerate Pipeline MomentumRead More January 5, 2024Clarametyx Biosciences Announces $33 Million Series A Financing to Advance Anti-Biofilm Biologics for Serious Bacterial InfectionsRead More June 1, 2023Clarametyx Announces Positive Early Phase 1 Safety Findings on CMTX-101, Immune-Enabling Antibody TherapyRead More May 30, 2023Clarametyx Biosciences Announces Changes to Its Scientific Advisory BoardRead More November 30, 2022Clarametyx Initiates Phase 1 Study of Immune-Enabling Antibody Therapy CMTX-101 Against Community-Acquired Bacterial PneumoniaRead More
